| Nov 7 |
Aprea Therapeutics GAAP EPS of -$0.64
|
| Nov 7 |
Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates
|
| Nov 7 |
Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
|
| Nov 6 |
Pacira (PCRX) Q3 Earnings Beat Estimates
|
| Oct 24 |
Aprea Therapeutics presents preliminary results on APR-1051
|
| Oct 23 |
Insider Spends US$132k Buying More Shares In Aprea Therapeutics
|
| Oct 23 |
Aprea Therapeutics falls on data from APR-1051 study in cancer-associated gene alterations
|
| Oct 23 |
Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
|
| Oct 14 |
Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit
|
| Sep 25 |
Aprea Therapeutics to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
|
